An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects. Researchers from The University of Texas MD Anderson Cancer Center presented interim findings of the multi-center Phase...
Micromet, Inc. (Nasdaq: MITI) announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL). A high objective response rate was maintained among patients treated with...